![]() |
产地 | 中国 |
品牌 | 爱必信(absin) |
货号 | abs816918 |
用途 | 见爱必信官网 |
英文名称 | 见爱必信官网 |
包装规格 | 100mg,100mg,100mg,100mg,50mg,50mg,50mg,50mg,200mg,200mg,200mg,200mg,500mg,500mg,500mg,500mg |
纯度 | >98%% |
CAS编号 | 474-25-9 |
别名 | 鹅去氧胆酸 |
是否进口 | 否 |
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Chenodeoxycholic acid 产品别名:见爱必信官网 英文别名:Chenodeoxycholic acid 靶点:Steroids CAS:474-25-9 纯度:>98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: Chenodeoxycholic Acid (CDCA), is a hydrophobic primary bile acid that activates nuclear receptors(FXR) involved in cholesterol metabolism. 溶解性:DMSO : ≥ 50 mg/mL (127.37 mM) 体外研究:
Chenodeoxycholic acid (CDCA) and Deoxycholic acid (DCA) both inhibits 11 beta HSD2 with IC(50) values of 22 mM and 38 mM, respectively and causes cortisol-dependent nuclear translocation and increases transcriptionalactivity of mineralocorticoid receptor (MR). Chenodeoxycholic acid is able to stimulate Ishikawa cell growth by inducing a significant increase in Cyclin D1 protein and mRNA expression through the activation of the membrane G protein-coupled receptor (TGR5)-dependent pathway. Chenodeoxycholic acid (CDCA) induces LDL receptor mRNA levels approximately 4 fold and mRNA levels for HMG-CoA reductase and HMG-CoA synthase two fold in a cultured human hepatoblastoma cell line, Hep G2. Chenodeoxycholic acid-induced Isc is inhibited (≥67%) by Bumetanide, BaCl2, and the cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor CFTRinh-172. Chenodeoxycholic acid-stimulated Isc is decreased 43% by the adenylate cyclase inhibitor MDL12330A and Chenodeoxycholic acid increases intracellular cAMP concentration. Chenodeoxycholic acid treatment activates C/EBPβ, as shown by increases in its phosphorylation, nuclear accumulation, and expression in HepG2 cells. Chenodeoxycholic acid enhances luciferase gene transcription from the construct containing -1.65-kb GSTA2 promoter, which contains C/EBP response element (pGL-1651). Chenodeoxycholic acid treatment activates AMP-activated protein kinase (AMPK), which leads to extracellular signal-regulated kinase 1/2 (ERK1/2) activation, as evidenced by the results of experiments using a dominant-negative mutant of AMPKα and chemical inhibitor. 体内研究:
产品信息订购:
|